icon-folder.gif   Conference Reports for NATAP  
 
  65th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 7-11 2014
Back grey_arrow_rt.gif
 
 
 
Phase 1a Safety and Pharmacokinetics of NVR 3-778, a Potential First-In-Class HBV Core Inhibitor
 
 
  Reported by Jules Levin
AASLD 2014 Nov 7-11 Boston
 
E.J. Gane1, C. Schwabe2, K. Walker2, L. Flores3, G.D. Hartman3, K. Klumpp3, S. Liaw3 and N.A. Brown3
1New Zealand Liver Transplant Unit, Auckland City Hospital, Auckland, New Zealand; 2Clinical Trials Unit, Auckland Clinical Studies, Auckland, New Zealand; 3Novira Therapeutics, Inc., Doylestown, PA , U.S.A.

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif